Abstract
Immune modulating drugs such as thiopurines (azathioprine and 6-mercaptopurine) and methotrexate has been a mainstay for treatment of inflammatory bowel disease (IBD) for decades. However, despite widely used in IBD, questions still remain concerning the most rational treatment regimens of these agents. Results from a range of recent studies necessitate increased awareness on how to best use these potent drugs in the clinic. As controversy still remains regarding the most appropriate use of immunomodulators, this review is based on scrutinizing the current literature, with emphasis on randomized controlled trials and Cochrane reviews, focusing on aspects that can lead to optimal and evidence-based thiopurine and methotrexate treatment strategies in IBD.
| Original language | English |
|---|---|
| Journal | Expert Review of Gastroenterology & Hepatology |
| Volume | 9 |
| Issue number | 2 |
| Pages (from-to) | 177-189 |
| Number of pages | 13 |
| ISSN | 1747-4124 |
| DOIs | |
| Publication status | Published - 1 Feb 2015 |
Keywords
- 6-Mercaptopurine
- Azathioprine
- Humans
- Immunologic Factors
- Immunomodulation
- Inflammatory Bowel Diseases
- Methotrexate
- Treatment Outcome